Page 272 - Haematologica Vol. 109 - July 2024

LETTER TO THE EDITOR
A
BC
DE
Figure 2. The presence of TP53, SF3B1, or ATM mutations is associated with inferior outcomes in patients with chronic lympho- cytic leukemia or small lymphocytic lymphoma. (A) Distributions of baseline mutations between patients who developed pro- gressive disease and those who did not were compared using proportions. (B-E) The association between genetic mutations and progression-free survival (PFS, defined as time from the date of first zanubrutinib dose to date of first progression of disease or death) was quantified by the log-rank test and hazard ratio and summarized by the Kaplan-Meier method. As of June 6, 2022, the data cutoff, patients were censored for PFS if: (i) they had no documented disease progression or death; (ii) they initiated subsequent anti-cancer therapy prior to progressive disease; or (iii) they progressed or died after more than one consecutive missed disease assessment. All analyses were performed using either R or SAS (version 9.4). Patients with mutations in TP53, SF3B1, and ATM, but not NOTCH1, showed shorter PFS. MUT: mutant; WT, wild type; PFS: progression-free survival.
Haematologica | 109 July 2024
2286